Twenty patients with hidradenitis suppurativa and obesity receiving semaglutide >1mg weekly for six months experienced dramatic improvements: 21.4kg average weight loss, reduced disease severity across all Hurley stages, 8.8-point improvement in quality of life scores, and 4.1-point reduction in pain scales. Critically, when researchers adjusted for weight changes, the dermatologic benefits persisted, indicating semaglutide's direct anti-inflammatory effects on this debilitating skin condition. This finding extends semaglutide's therapeutic potential beyond diabetes and obesity into autoimmune dermatology. Hidradenitis suppurativa affects 1-4% of adults with painful, recurring abscesses that significantly impair quality of life and often resist conventional treatments. The condition's strong metabolic component makes GLP-1 receptor agonists theoretically appealing, but clinical evidence was previously limited. While promising, this small open-label study requires larger randomized controlled trials to establish causality and optimal dosing protocols. The dual benefit—metabolic improvement plus direct anti-inflammatory action—positions semaglutide as a potentially transformative treatment for patients suffering from both obesity and this chronically painful dermatologic condition.